A study conducted by the European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group and published in Lancet Oncology does not support administration of intensified doxorubicin and ifosfamide regimen for palliation of advanced or metastatic soft tissue sarcoma, unless the treatment objective is to shrink the tumour. Read more
here.
No comments:
Post a Comment